Recursion Pharmaceuticals’ (RXRX) Buy Rating Reiterated at Needham & Company LLC

Needham & Company LLC reaffirmed their buy rating on shares of Recursion Pharmaceuticals (NASDAQ:RXRX – Free Report) in a report issued on Tuesday morning,Benzinga reports. The brokerage currently has a $11.00 price target on the stock. RXRX has been the subject of several other research reports. KeyCorp decreased their target price on Recursion Pharmaceuticals from […]